Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.32 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.32 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490962 | 1.00 | KIF11 (0.44) | KIF11ERN1PDE2AKDM1ACES2 | |
| SCHEMBL12974456 | 0.79 | CA2 (0.44) | ERN1 | |
| SCHEMBL5594767 | 0.77 | KIF11 (0.37) | KIF11PDE2AKDM1A | |
| SCHEMBL20165547 | 0.77 | KIF11 (0.37) | KIF11PDE2ACES2TMPRSS4 | |
| SCHEMBL19865216 | 0.77 | KIF11 (0.41) | KIF11ERN1KDM1ACES2PTPN7 | |
| SCHEMBL102339 | 0.77 | KIF11 (0.41) | KIF11ERN1KDM1A | |
| SCHEMBL4346966 | 0.77 | KIF11 (0.41) | KIF11TMPRSS4 | |
| SCHEMBL30524326 | 0.77 | PDE2A (0.40) | KIF11PDE2AKDM1ACES2 | |
| SCHEMBL8160495 | 0.77 | PDE2A (0.40) | KIF11PDE2AKDM1ACES2 | |
| SCHEMBL28453327 | 0.76 | PDE2A (0.45) | KIF11PDE2AKDM1ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-116744918-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4221702-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4221703-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023043836-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022072512-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022072517-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | KIF11 4244/4885ERN1 1599/4885PDE2A 931/4885 |
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | KIF11 4244/4885ERN1 1599/4885PDE2A 931/4885 |
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | KIF11 4244/4885ERN1 1599/4885PDE2A 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.